Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387181 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1UCHL1ALDH1A1 | |
| SCHEMBL12553792 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1UCHL1ALDH1A1 | |
| SCHEMBL3949196 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1UCHL1ALDH1A1 | |
| SCHEMBL24826386 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1UCHL1ALDH1A1 | |
| SCHEMBL9383410 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1UCHL1ALDH1A1 | |
| SCHEMBL24894673 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1UCHL1ALDH1A1 | |
| SCHEMBL30538732 | 0.88 | NR1H2 (0.35) | NR1H2ABCB1PARP1ALDH1A1CHRM2 | |
| SCHEMBL1526483 | 0.88 | NR1H2 (0.35) | NR1H2ABCB1PARP1ALDH1A1CHRM2 | |
| SCHEMBL1526484 | 0.88 | NR1H2 (0.35) | NR1H2ABCB1PARP1ALDH1A1CHRM2 | |
| SCHEMBL12431668 | 0.86 | NR1H2 (0.37) | NR1H2ABCB1PARP1ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | NR1H2 557/4885ABCB1 14/4885PARP1 1294/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NR1H2 557/4885ABCB1 14/4885PARP1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.